{"id":23406,"date":"2024-03-26T08:49:40","date_gmt":"2024-03-26T07:49:40","guid":{"rendered":"https:\/\/ggba.swiss\/onward-medical-secures-eur-20-million-to-expand-its-spinal-cord-injury-therapies\/"},"modified":"2024-03-26T08:53:34","modified_gmt":"2024-03-26T07:53:34","slug":"eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/","title":{"rendered":"EUR 20 millions pour les th\u00e9rapies des l\u00e9sions de la moelle \u00e9pini\u00e8re d\u2019ONWARD Medical"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.onwd.com\/\">ONWARD Medical<\/a>, connue pour ses th\u00e9rapies pionni\u00e8res de stimulation de la moelle \u00e9pini\u00e8re, a lev\u00e9 EUR 20 millions dans le cadre d&rsquo;un placement priv\u00e9 et d&rsquo;une introduction en bourse (IPO). Cette injection strat\u00e9gique de capitaux servira de catalyseur pour l&rsquo;approbation et le lancement des premiers produits de la soci\u00e9t\u00e9, qui sont con\u00e7us pour transformer la vie des personnes souffrant de l\u00e9sions de la moelle \u00e9pini\u00e8re.<\/p>\n\n\n\n<p>\u00c9tablie dans l&rsquo;environnement acad\u00e9mique et de recherche de l&rsquo;EPFL, ONWARD Medical a fait des progr\u00e8s significatifs depuis sa cr\u00e9ation. Avec un historique d&rsquo;obtention de financements substantiels, dont un notable <a href=\"https:\/\/ggba.swiss\/fr\/onward-spin-off-de-lepfl-leve-32-millions-therapies-de-moelle-epiniere\/\">EUR 32 millions en 2021<\/a>, et son <a href=\"https:\/\/ggba.swiss\/fr\/onward-medical-entre-en-bourse-et-leve-chf-93-millions\/\">entr\u00e9e en bourse r\u00e9ussie levant CHF 93 millions<\/a>, ONWARD a \u00e9t\u00e9 \u00e0 l&rsquo;avant-garde du d\u00e9veloppement de th\u00e9rapies telles que ARC-EX et ARC-IM. Ces th\u00e9rapies, con\u00e7ues pour restaurer le mouvement et la fonction, ont d\u00e9j\u00e0 montr\u00e9 des <a href=\"https:\/\/ggba.swiss\/fr\/onward-simmisce-dans-la-sante-federale-americaine-pour-aider-les-veterans-handicapes\/\">r\u00e9sultats prometteurs lors d&rsquo;essais cliniques et ont re\u00e7u la Breakthrough Device Designation de la FDA<\/a>.<\/p>\n\n\n\n<p>Le nouveau capital de EUR 20 millions sera strat\u00e9giquement r\u00e9parti entre plusieurs domaines cl\u00e9s : environ 45% pour la recherche et le d\u00e9veloppement du syst\u00e8me ARC-EX pour restaurer la fonction de la main et du bras et du syst\u00e8me ARC-IM pour am\u00e9liorer la r\u00e9gulation de la pression art\u00e9rielle apr\u00e8s un accident vasculaire c\u00e9r\u00e9bral (AVC). En outre, 15% sont r\u00e9serv\u00e9s \u00e0 l&rsquo;\u00e9tablissement d&rsquo;une pr\u00e9sence commerciale en pr\u00e9vision du lancement du syst\u00e8me ARC-EX aux \u00c9tats-Unis, y compris la formation d&rsquo;une \u00e9quipe de vente et le d\u00e9veloppement de mat\u00e9riel \u00e9ducatif. Enfin, 35% serviront \u00e0 am\u00e9liorer l&rsquo;infrastructure op\u00e9rationnelle et qualitative, les 5% restants \u00e9tant destin\u00e9s \u00e0 financer les besoins en fonds de roulement.<\/p>\n\n\n\n<p>Ce tour de table souligne non seulement la confiance des investisseurs institutionnels, de certains fondateurs et de la direction, mais aussi l&rsquo;enthousiasme pour la participation des investisseurs particuliers en France par le biais de la plateforme PrimaryBid. A l&rsquo;issue de ce tour de table, les actionnaires de r\u00e9f\u00e9rence INKEF Capital et EQT Life Sciences d\u00e9tiendront respectivement 11,5% et 11,2% du capital de la soci\u00e9t\u00e9, soulignant ainsi la confiance des investisseurs dans la mission et les technologies d&rsquo;ONWARD.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ONWARD Medical, un pionnier des th\u00e9rapies de stimulation de la moelle \u00e9pini\u00e8re, a lev\u00e9 EUR 20 millions par le biais d&rsquo;un placement priv\u00e9 et d&rsquo;une offre publique, marquant une \u00e9tape importante dans l&rsquo;avancement et le d\u00e9ploiement de ses traitements innovants.<\/p>\n","protected":false},"author":6,"featured_media":23403,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1148,1181,1163,1141],"class_list":["post-23406","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-financing-fr-2","tag-medical-devices-fr","tag-medtech-fr-2","tag-personalized-medicine-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EUR 20 millions pour les th\u00e9rapies d\u2019ONWARD Medical | GGBa<\/title>\n<meta name=\"description\" content=\"ONWARD Medical, un pionnier des th\u00e9rapies de la moelle \u00e9pini\u00e8re, a lev\u00e9 EUR 20 millions via un placement priv\u00e9 et d&#039;une offre publique.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EUR 20 millions pour les th\u00e9rapies d\u2019ONWARD Medical | GGBa\" \/>\n<meta property=\"og:description\" content=\"ONWARD Medical, un pionnier des th\u00e9rapies de la moelle \u00e9pini\u00e8re, a lev\u00e9 EUR 20 millions via un placement priv\u00e9 et d&#039;une offre publique.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-26T07:49:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-26T07:53:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Onward-Medical-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"EUR 20 millions pour les th\u00e9rapies des l\u00e9sions de la moelle \u00e9pini\u00e8re d\u2019ONWARD Medical\",\"datePublished\":\"2024-03-26T07:49:40+00:00\",\"dateModified\":\"2024-03-26T07:53:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/\"},\"wordCount\":400,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Onward-Medical-1180x811-1.png\",\"keywords\":[\"Financing\",\"Medical Devices\",\"Medtech\",\"Personalized Medicine\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/\",\"name\":\"EUR 20 millions pour les th\u00e9rapies d\u2019ONWARD Medical | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Onward-Medical-1180x811-1.png\",\"datePublished\":\"2024-03-26T07:49:40+00:00\",\"dateModified\":\"2024-03-26T07:53:34+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"ONWARD Medical, un pionnier des th\u00e9rapies de la moelle \u00e9pini\u00e8re, a lev\u00e9 EUR 20 millions via un placement priv\u00e9 et d'une offre publique.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Onward-Medical-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Onward-Medical-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"Ce financement devrait permettre \u00e0 la soci\u00e9t\u00e9 d'\u00e9tendre sa marge de man\u0153uvre financi\u00e8re jusqu'\u00e0 la mi-2025, alors qu'elle se pr\u00e9pare \u00e0 l'approbation et au lancement de produits pionniers con\u00e7us pour am\u00e9liorer la vie des personnes souffrant de l\u00e9sions de la moelle \u00e9pini\u00e8re (LM). | \u00a9 ONWARD Medical.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EUR 20 millions pour les th\u00e9rapies des l\u00e9sions de la moelle \u00e9pini\u00e8re d\u2019ONWARD Medical\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EUR 20 millions pour les th\u00e9rapies d\u2019ONWARD Medical | GGBa","description":"ONWARD Medical, un pionnier des th\u00e9rapies de la moelle \u00e9pini\u00e8re, a lev\u00e9 EUR 20 millions via un placement priv\u00e9 et d'une offre publique.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/","og_locale":"fr_FR","og_type":"article","og_title":"EUR 20 millions pour les th\u00e9rapies d\u2019ONWARD Medical | GGBa","og_description":"ONWARD Medical, un pionnier des th\u00e9rapies de la moelle \u00e9pini\u00e8re, a lev\u00e9 EUR 20 millions via un placement priv\u00e9 et d'une offre publique.","og_url":"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-03-26T07:49:40+00:00","article_modified_time":"2024-03-26T07:53:34+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Onward-Medical-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"EUR 20 millions pour les th\u00e9rapies des l\u00e9sions de la moelle \u00e9pini\u00e8re d\u2019ONWARD Medical","datePublished":"2024-03-26T07:49:40+00:00","dateModified":"2024-03-26T07:53:34+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/"},"wordCount":400,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Onward-Medical-1180x811-1.png","keywords":["Financing","Medical Devices","Medtech","Personalized Medicine"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/","url":"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/","name":"EUR 20 millions pour les th\u00e9rapies d\u2019ONWARD Medical | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Onward-Medical-1180x811-1.png","datePublished":"2024-03-26T07:49:40+00:00","dateModified":"2024-03-26T07:53:34+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"ONWARD Medical, un pionnier des th\u00e9rapies de la moelle \u00e9pini\u00e8re, a lev\u00e9 EUR 20 millions via un placement priv\u00e9 et d'une offre publique.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Onward-Medical-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Onward-Medical-1180x811-1.png","width":1180,"height":811,"caption":"Ce financement devrait permettre \u00e0 la soci\u00e9t\u00e9 d'\u00e9tendre sa marge de man\u0153uvre financi\u00e8re jusqu'\u00e0 la mi-2025, alors qu'elle se pr\u00e9pare \u00e0 l'approbation et au lancement de produits pionniers con\u00e7us pour am\u00e9liorer la vie des personnes souffrant de l\u00e9sions de la moelle \u00e9pini\u00e8re (LM). | \u00a9 ONWARD Medical."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/eur-20-millions-pour-les-therapies-des-lesions-de-la-moelle-epiniere-donward-medical\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"EUR 20 millions pour les th\u00e9rapies des l\u00e9sions de la moelle \u00e9pini\u00e8re d\u2019ONWARD Medical"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/23406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=23406"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/23406\/revisions"}],"predecessor-version":[{"id":23408,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/23406\/revisions\/23408"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/23403"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=23406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=23406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=23406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}